Nektar Therapeutics(NKTR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:19 PM ET (Korea 10/31 06:19)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -6.7 | Insider Own | 3.21% | Shs Outstand | 34.1M | Perf Week | 4.43% |
| Market Cap | 1.33B | Forward P/E | - | EPS next Y | -29.95% | Insider Trans | -2.88% | Shs Float | 33.0M | Perf Month | -17.28% |
| Enterprise Value | 0.78B | PEG | - | EPS next Q | -2.07 | Inst Own | 103.74% | Short Float | 21.17% | Perf Quarter | -44.94% |
| Income | -0.16B | P/S | 24.31 | EPS this Y | 16.92% | Inst Trans | 29.5% | Short Ratio | 6.42 | Perf Half Y | -55.04% |
| Sales | 0.05B | P/B | 1.47 | EPS next 5Y | -3.29% | ROA | -24.12% | Short Interest | 7.00M | Perf YTD | -8.07% |
| Book/sh | 26.46 | P/C | 1.94 | EPS past 3/5Y | 30.93% 23.59% | ROE | -35.75% | 52W High | -64.34% ($109.00) | Perf Year | -38.11% |
| Cash/sh | 20.04 | P/FCF | - | Sales past 3/5Y | -15.66% -18.43% | ROIC | -15.46% | 52W Low | 16.38% ($33.40) | Perf 3Y | 465.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 23.1% | Gross Margin | 98.73% | Volatility(W/M) | 3.34% 4.93% | Perf 5Y | -82.91% |
| Dividend TTM | - | EV/Sales | 14.26 | Sales Y/Y TTM | -27.15% | Oper. Margin | -239.32% | ATR (14) | 2.31 | Perf 10Y | -78.42% |
| Dividend Ex-Date | - | Quick Ratio | 10.42 | EPS Q/Q | 58.38% | Profit Margin | -287.84% | RSI (14) | 34.73 | Recom | 1.53 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.42 | Sales Q/Q | -9.34% | SMA20 | 0.37% ($38.73) | Beta | -0.59 | Target Price | $133.08 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/11/12 | SMA50 | -30.2% ($55.69) | Rel Volume | 0.55 | Prev Close | $39.18 |
| Employees | 63 | LT Debt/Eq | 0.13 | EPS/Sales Surpr. | 37.6% -2.82% | SMA200 | -40.21% ($65.01) | Avg Volume(3M) | 1.09M | Price | $38.87 |
| IPO | 1994/5/3 | Option/Short | Yes/Yes | Trades | 6830 | Volume | 601,063 | Change | -0.79% |
🧬 A US clinical-stage biotech company developing treatments for immune diseases. Leveraging a mechanism that modulates the immune system, it develops drug candidates targeting conditions such as atopic dermatitis and autoimmune diseases, with a lead candidate in the late-stage clinical pipeline. This biotech is pursuing entry into the underserved immune disease market through its differentiated approach to immune modulation.
Over the past 1 year, on the lower side
64% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
Next earnings report: November 12
11 days to go.
NKTR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +16.9% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,431. Peers typically go for $1,268.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -82.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.2% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #137 of 597 in the industry
Based on market cap of $1B.
TSHA#135 Taysha Gene Therapies Inc $1B PER - 
OMER#136 Omeros Corp $1B PER 12.8 NKTR#137 Nektar Therapeutics $1B PER - 
DMRA#138 Damora Therapeutics Inc $1B PER - 
KARD#139 Kardigan Inc $1B PER - 
FAQ
What kind of company is NKTR?
NKTR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NKTR?
The market cap of NKTR is approximately $1.3B, ranking 2,375 within its sector.
What is the 52-week high and low for NKTR?
NKTR has recorded a 52-week high of $109.00 and a low of $33.40.
